文献速递肥胖与代谢综合征糖尿病

血清血小板反应蛋白-2水平与代谢综合征及代谢相关脂肪性肝病严重程度密切相关

Serum Thrombospondin-2 Levels Are Closely Associated With the Severity of Metabolic Syndrome and Metabolic Associated Fatty Liver Disease.
PubMed 文献 · J Clin Endocrinol Metab · 2022-01-01

研究连续纳入252例接受减重手术的病态肥胖个体,检测血清TSP2水平并行肝活检。血清TSP2在MetS组高于非MetS组,且与MetS组分数量及糖代谢指标正相关;TSP2可区分MASH与非MASH较轻组,识别高危MASH的AUC为0.84(95%CI 0.70-0.98)。

要点

  • 肥胖患者中MetS组血清TSP2为1.58 ng/mL,高于非MetS组的1.28 ng/mL(P=.006)。
  • MASH组血清TSP2为1.74 ng/mL,高于正常肝脏、单纯脂肪变及临界MASH组(P<.05)。
  • 高血清TSP2识别高危MASH的AUC为0.84(95%CI 0.70-0.98)。

核心结论

  • 血清TSP2与MetS和MAFLD的严重程度及进展密切相关,是区分MASH与良性脂肪变、识别肥胖个体中高危MASH患者的有前景的无创生物标志物。

研究设计与样本

  • 连续纳入252例接受减重手术的病态肥胖个体,采集血液样本、临床数据及肝活检组织。
  • 肝活检组织病理学样本由3名独立病理学家以盲法方式检查。
  • 血清TSP2水平采用酶联免疫吸附试验测定。

主要发现

  • 肥胖患者中MetS组血清TSP2为1.58(1.07-2.20)ng/mL,高于非MetS组的1.28(0.84-1.73)ng/mL(P=.006)。
  • 校正常规混杂因素后,血清TSP2与MetS组分数量增加、空腹血糖、糖化血红蛋白、空腹胰岛素、C肽及胰岛素抵抗稳态模型评估正相关。
  • MASH组血清TSP2为1.74(1.32-3.09)ng/mL,高于正常肝脏组的1.41(1.04-1.63)ng/mL、单纯脂肪变组的1.45(0.89-1.92)ng/mL及临界MASH组的1.30(0.99-2.17)ng/mL(P<.05)。
  • 升高的血清TSP2与肝脂肪变、炎症、纤维化及肝功能异常的严重程度正相关,且不依赖于年龄、性别和肥胖程度。
  • 高血清TSP2识别高危MASH的曲线下面积为0.84(95%CI 0.70-0.98)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Metabolic associated fatty liver disease (MAFLD) is the hepatic manifestation of obesity-related metabolic syndrome (MetS). Noninvasive biomarkers for monitoring the progression and severity of these metabolic comorbidities are needed. OBJECTIVES: To investigate the associations of serum thrombospondin-2 (TSP2) with MetS and MAFLD severity, and the potential diagnostic value of serum TSP2 for identifying at-risk metabolic associated steatohepatitis (MASH). METHODS: Blood samples, clinical data, and liver biopsies were collected from consecutively recruited 252 individuals with morbid obesity receiving bariatric surgery. Histopathology samples of liver biopsies were examined in a blinded fashion by 3 independent pathologists. Serum TSP2 levels were measured by enzyme-linked immunosorbent assay. RESULTS: Serum TSP2 levels were significantly elevated in MetS (1.58 [1.07-2.20] ng/mL) compared with non-MetS (1.28 [0.84-1.73] ng/mL; P = .006) in obese patients and positively correlated with increasing number of the MetS components, fasting glucose, glycated hemoglobin, fasting insulin, C-peptide, and homeostatic model assessment of insulin resistance after adjustment of conventional confounders. Serum TSP2 levels differentiated MASH (1.74 [1.32-3.09] ng/mL) from the other non-MASH less severe groups: normal liver (1.41 [1.04-1.63] ng/mL), simple steatosis (1.45 [0.89-1.92] ng/mL), and borderline MASH (1.30 [0.99-2.17] ng/mL) (P < .05). Elevated serum TSP2 was positively associated with the severity of hepatic steatosis, inflammation, fibrosis, and abnormal liver function independent of age, sex and adiposity. Furthermore, high serum TSP2 identified at-risk MASH with area under the operating curve of 0.84 (95% CI 0.70-0.98). CONCLUSION: Serum TSP2 is closely associated with severity and progression of MetS and MAFLD, and is a promising noninvasive biomarker for differentiating MASH from benign steatosis and identifying at-risk MASH patients among individuals with obesity.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Wu X, Cheung CKY, Ye D, et al. Serum Thrombospondin-2 Levels Are Closely Associated With the Severity of Metabolic Syndrome and Metabolic Associated Fatty Liver Disease. J Clin Endocrinol Metab. 2022. PMID: 35532410. doi:10.1210/clinem/dgac292

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。